- Home
- TYGO vs WHWK Comparison
TYGO vs WHWK Comparison
Compare TYGO & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- WHWK
- Stock Information
- Founded
- TYGO 2007
- WHWK 2007
- Country
- TYGO United States
- WHWK United States
- Employees
- TYGO N/A
- WHWK N/A
- Industry
- TYGO Semiconductors
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- WHWK Health Care
- Exchange
- TYGO Nasdaq
- WHWK Nasdaq
- Market Cap
- TYGO 116.0M
- WHWK 95.2M
- IPO Year
- TYGO N/A
- WHWK N/A
- Fundamental
- Price
- TYGO $1.77
- WHWK $2.29
- Analyst Decision
- TYGO Strong Buy
- WHWK
- Analyst Count
- TYGO 1
- WHWK 0
- Target Price
- TYGO $6.00
- WHWK N/A
- AVG Volume (30 Days)
- TYGO 630.6K
- WHWK 218.8K
- Earning Date
- TYGO 10-28-2025
- WHWK 11-06-2025
- Dividend Yield
- TYGO N/A
- WHWK N/A
- EPS Growth
- TYGO N/A
- WHWK N/A
- EPS
- TYGO N/A
- WHWK N/A
- Revenue
- TYGO $90,781,000.00
- WHWK $14,384,000.00
- Revenue This Year
- TYGO $95.15
- WHWK N/A
- Revenue Next Year
- TYGO $21.54
- WHWK N/A
- P/E Ratio
- TYGO N/A
- WHWK N/A
- Revenue Growth
- TYGO 97.41
- WHWK N/A
- 52 Week Low
- TYGO $0.58
- WHWK $1.39
- 52 Week High
- TYGO $4.50
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- TYGO 39.87
- WHWK 54.12
- Support Level
- TYGO $1.59
- WHWK $1.97
- Resistance Level
- TYGO $4.50
- WHWK $2.27
- Average True Range (ATR)
- TYGO 0.37
- WHWK 0.14
- MACD
- TYGO -0.03
- WHWK 0.00
- Stochastic Oscillator
- TYGO 6.70
- WHWK 90.91
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.